EP1501558A1 - Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine - Google Patents

Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine

Info

Publication number
EP1501558A1
EP1501558A1 EP03749866A EP03749866A EP1501558A1 EP 1501558 A1 EP1501558 A1 EP 1501558A1 EP 03749866 A EP03749866 A EP 03749866A EP 03749866 A EP03749866 A EP 03749866A EP 1501558 A1 EP1501558 A1 EP 1501558A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical formulation
thrombin
formulation according
resorbable
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03749866A
Other languages
German (de)
English (en)
Inventor
Frank Gerhards
Rui-Miguel Pereira-Paz
Doris Universitätsklinikum Aachen KLEE
Hartwig Universitätsklinikum Aachen HÖCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinisch Westlische Technische Hochschuke RWTH
Original Assignee
Rheinisch Westlische Technische Hochschuke RWTH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheinisch Westlische Technische Hochschuke RWTH filed Critical Rheinisch Westlische Technische Hochschuke RWTH
Publication of EP1501558A1 publication Critical patent/EP1501558A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen

Definitions

  • the present invention relates to a resorbable pharmaceutical formulation for continuous local thrombin release comprising thrombin which is embedded in resorbable spheres of polymers, the spheres being incorporated in a sponge.
  • the formulation according to the invention provides a resorbable hamostatic agent for use in surgery, in particular dental surgery / in dento alveolar interventions.
  • anticoagulation due to various diseases, the number of patients requiring therapeutic anticoagulation (anticoagulation) is increasing. These include, for example, patients with artificial heart valve prostheses or patients who have had a stroke or venous thrombosis.
  • vitamin K antagonists coumarin derivatives such as e.g.
  • Warfarin® Form of Warfarin®
  • heparin has a significantly shorter half-life, which makes it easier to control the anticoagulant if bleeding complications occur, without having to forego the necessary protection against thrombosis.
  • postoperative bleeding is also caused by the piasmin system.
  • the piasmin system the physiological antagonist of the blood coagulation system, ensures a dissolution of at a systemic level Blood clots. However, this function is not desirable if there is an increased risk of bleeding after surgery.
  • the optimal local wound care is the same for both concepts: after the extraction of the teeth or after a smaller dental intervention, the bone wound is tamponized with a collagen vial (e.g. Lyostypt) or a gelatin sponge (e.g. Topostatin).
  • a collagen vial e.g. Lyostypt
  • a gelatin sponge e.g. Topostatin
  • the mechanical compression of the bone wound brought about by this can achieve an initial hemostasis.
  • a local hemostatic agent based on thrombin or fibrin glue preparation can also be applied to the bone wound.
  • the mucosal wound is then closed with saliva-tight atraumatic sutures.
  • a wound protection plate made of plastic is often used in patients and attached to the remaining teeth.
  • the object of the present invention is therefore to provide a pharmaceutical formulation with which the active end product of the blood coagulation cascade, thrombin, can be made available over a limited period of time.
  • the period until stable intraoral wound healing is considered to be the required period of time. This corresponds to 7 to 10 days. After this period, stable wound healing has occurred, which means that external mechanical influences on the wound can no longer have any effect.
  • thrombin is embedded in resorbable spheres, preferably from commercially available polymers that are already used for other medical devices (e.g. surgical sutures) (see Figure 1).
  • spheres in the context of the invention is understood to mean particles, capsules or liposomes which contain the active ingredient embedded, enclosed, dispersed or dissolved, as described, for example, in Voigt, Pharmaceutical Technology, Deutscher maschinerverlag Stuttgart, 2000, pages 467-471.
  • spheres in the sense of the present invention is understood in particular to mean microparticles or nanoparticles which contain an active ingredient embedded in a polymer matrix without the formation of a separate capsule skin
  • Spheres with a size of 0.1 to 1000 / ym are preferred, very particularly with a size of 10 to 150 ⁇ m.
  • the loading of the spheres can be 0.1 to 20%, depending on the corresponding thrombin preparation, and the loading of the collagen sponge can be 0.1 to 50%.
  • the total dose should be 1 I.U. up to 2000 IU, preferably 250 IU up to 1000 IU Thrombin per implant.
  • the spheres can be produced with the aid of known processes, in particular emulsion techniques (w / o; o / w; w / o / w - emulsion evaporation or extraction method) or spray drying.
  • emulsion techniques w / o; o / w; w / o / w - emulsion evaporation or extraction method
  • spray drying emulsion techniques
  • the methods are described in the prior art.
  • EP 0 330 180 describes microspheres of the polylactic acid type containing physiologically active substances and processes for their production.
  • Other manufacturing processes include Müller RH and Hildebrand GE, Pharmaceutical Technology: Modern Pharmaceutical Forms, Stuttgart, pp. 243-258 and S339-355, Eldrigé J. et al., J. Controlled Release 1990, 11, 205 -214; Jeffery J. et al. Pharm. Res.
  • Resorbable polymers used according to the invention for producing the resorbable spheres include poly sugar and their derivatives, polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polylactic acid (PLA), polylactides, polyhydroxybutyrate (PHB), poly-L-lysine, their homologues and cocondensates, lactic acid Glycolic acid copolymer (PLG), in particular Resomer RG 504 and 505 from Boehringer Ingelheim.
  • PVA polyvinyl alcohol
  • PVP polyvinyl pyrrolidone
  • PLA polylactic acid
  • PHB polyhydroxybutyrate
  • PEG poly-L-lysine
  • Other usable polymers are disclosed, inter alia, in Müller RH and Hildebrand GE, Pharmaceutical Technology: Modern Pharmaceutical Forms,ticianliche Verlagsgesellschaft Stuttgart, 1998, pp. 243-258 and S339-355.
  • the spheres thus obtained are in turn incorporated into resorbable sponges, in particular collagen sponges.
  • This is done, for example, by freeze-drying an aqueous collagen or an aqueous collagen suspension or gelatin solution in which the spheres are uniformly dispersed.
  • the production of collagen sponges is e.g. in US 4,515,637, EP 562862 and by Chvapil, J. Biomed. Mater. Res. H, 721-741 (1977).
  • the collagen used according to the present invention should preferably be soluble in vivo by enzymatic degradation or other biological processes.
  • Preferred is native collagen in its potentially soluble form or natural insoluble collagen which is inherently cross-linked and is insoluble in either an acidic or alkaline medium such as e.g. also described in US 4,515,637.
  • the collagen used is preferably type 1 collagen.
  • the origin of the collagen for use in the present invention is not particularly limited.
  • collagen is used which is derived from the skin, bone, cartilage, tendons, internal organs, etc. of a mammal such as e.g. comes from humans, horses, cattle, pigs, sheep, rabbits, mice.
  • Collagen-like protein derived from birds, fish or the like can also be used.
  • Genetically engineered collagen can also be used, and genetic engineering is currently in progress (e.g. ZymoGenetics, WA, U.S.A.)
  • the thrombin used in the present invention can be obtained from a variety of sources, e.g. pooled human or animal plasma.
  • Bovine thrombin is e.g. available from a variety of commercial sources.
  • Recombinant thrombin can also be used in accordance with the invention (e.g. ZymoGenetics, WA, U.S.A.).
  • thrombin-like compounds such as proteolytic snake venom, and thrombin precursors such as prothrombin can be used as sources for thrombin.
  • thrombin as used here also includes thrombin precursors and thrombin-like compounds and refers to all proteins and amino acid polymers of natural or synthetic origin which are able to catalyze the formation of fibrin clots from fibrinogen and / or to activate the blood platelets other coagulation factors such as factor VIII can also be used
  • This formulation according to the invention has various advantages since, on the one hand, the use of collagen sponges for mechanical wound compression and the platelet aggregation induced by collagen, the existing therapy concept is only slightly changed and, on the other hand, the healing of the wound is supported over a period of 7-10 days by the released thrombin , The platelet aggregation caused by collagen, through the release of mediators, activates plasmatic blood coagulation.
  • the release is preferably 0 to 14 days, particularly preferably 7 to 10 days.
  • the preparation can be supplemented with therapy-supporting antifibrinolytics such as tranexamic acid, ⁇ -amino caproic acid, 4- (aminomethyl) benzoic acid, aprotinin, EPO, acetaminonaphtone, thromboplastin, menadione sodium bisulfonate sulfonate sulfonate sulfonate sulfonate sulfonate, and add become.
  • antifibrinolytics such as tranexamic acid, ⁇ -amino caproic acid, 4- (aminomethyl) benzoic acid, aprotinin, EPO, acetaminonaphtone, thromboplastin, menadione sodium bisulfonate sulfonate sulfonate sulfonate sulfonate, and add become.
  • antifibrinolytics such as tranexamic acid,
  • Figure 2 shows a release profile of thrombin from poly (DL-lactide-co-glycolide) 50:50 (Boehringer Ingelheim RG 504) at 37 ° C in PBS buffer. The time-dependent cumulative thrombin release is shown, determined by means of the Bradford test measured in vitro over the release period of 28 days.
  • Figure 3 shows a release profile of thrombin from poly (DL-lactide-co-glycolide) 50:50 (Boehringer Ingelheim RG 504) at 37 ° C in PBS buffer.
  • the time-dependent cumulative thrombin release is shown, which is measured by the elimination of p-nitroaniline from the chromogenic substrate, in vitro over the release period of 28 days.
  • 1 NIH thrombin corresponds to 0.324 +/- 0.073 ⁇ g thrombin.
  • the amount of p-nitroaniline released is proportional to the active thrombin, the thrombin used had an activity of 50 NIH / mg.
  • the present invention further provides the use of the pharmaceutical formulation according to the invention as a local hemostatic agent, in particular for local hemostasis in blood-clot-inhibited / blood-coagulation-incompetent patients.
  • the cause of the anticoagulation can be iatrogenic, i.e. due to an inhibition of blood clotting due to the administration of vitamin K antagonists such as phenprocoumon or coumadin, platelet aggregation inhibitors such as acetylsalicylic acid, tirofiban, dipyramidol, ticiopidine or eptifibatide or is endogenously caused as in patients with a congenital defect in blood clotting in a mild form.
  • vitamin K antagonists such as phenprocoumon or coumadin
  • platelet aggregation inhibitors such as acetylsalicylic acid, tirofiban, dipyramidol, ticiopidine or eptifibatide
  • the frequency of postoperative bleeding in coagulation-incompetent patients is approximately 30% and the required duration of hospitalization is several days (on average 5 days).
  • the clinical use of the pharmaceutical formulation according to the invention significantly reduces the frequency of subsequent bleeding and thereby shortens the duration of hospitalization. It also enables certain outpatient procedures Interventions. In addition to a significantly reduced risk for the patients, this also means considerable cost savings in the healthcare system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques résorbables destinées à la libération continue locale de thrombine. La thrombine est enrobée dans des sphères en polymère résorbable, les sphères étant incorporées dans une éponge de collagène. La formulation selon l'invention propose un hémostyptique résorbable destiné à être utilisé en chirurgie, notamment en chirurgie dentaire dans le cas d'interventions dento-alvéolaires.
EP03749866A 2002-05-08 2003-05-05 Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine Withdrawn EP1501558A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10220030 2002-05-08
DE10220030 2002-05-08
PCT/EP2003/004680 WO2003094983A1 (fr) 2002-05-08 2003-05-05 Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine

Publications (1)

Publication Number Publication Date
EP1501558A1 true EP1501558A1 (fr) 2005-02-02

Family

ID=29413701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03749866A Withdrawn EP1501558A1 (fr) 2002-05-08 2003-05-05 Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine

Country Status (4)

Country Link
EP (1) EP1501558A1 (fr)
AU (1) AU2003232257A1 (fr)
CA (1) CA2485268A1 (fr)
WO (1) WO2003094983A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014973A (zh) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
WO2012146655A1 (fr) 2011-04-27 2012-11-01 Biom'up Compositions hémostatiques
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
EP2977066A3 (fr) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Composition hémostatique sèche
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
CN104163779B (zh) * 2014-06-06 2016-04-13 浙江工业大学 一种管式连续化制备亚硫酸氢钠甲萘醌的方法
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
PL3496770T3 (pl) 2016-08-12 2021-09-27 Biom'up France SAS Hemostatyczny płynny materiał
CN112055599A (zh) 2018-02-15 2020-12-08 比奥马普法国公司 多维止血产品及其制造方法
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
CN111053944B (zh) * 2019-11-28 2021-05-28 中国科学院大学温州研究院(温州生物材料与工程研究所) 一种载凝血酶微球-膨胀海绵复合止血材料及其制备方法及应用
CN114159623B (zh) * 2020-12-12 2022-11-08 复旦大学 一种自抗凝弹性体材料及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515637A (en) * 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
RU2193897C2 (ru) * 1996-04-04 2002-12-10 Бакстер Акциенгезельшафт Гемостатическая губка, основанная на коллагене, способ ее получения, повязка для ран, включающая такую губку, и набор для приготовления повязки для ран
EP1053753A1 (fr) * 1999-05-19 2000-11-22 Resorba Chirurgisches Nahtmaterial Franz Hiltner GmbH & Co. Support de médicaments à utilisation locale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03094983A1 *

Also Published As

Publication number Publication date
AU2003232257A1 (en) 2003-11-11
WO2003094983A1 (fr) 2003-11-20
CA2485268A1 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
US12544483B2 (en) Method for preparing a haemostatic composition
DE69813242T2 (de) Hemostatische verdichtungsmittel für gewebe
DE69433939T2 (de) Hämostatisches pflaster
Klokkevold et al. Effect of chitosan on lingual hemostasis in rabbits
DE69425509T2 (de) Lokale verabreichung von fibrinolyse verstärkendemitteln
DE69231421T2 (de) Fibrin oder fibrinogen sowie biologisch abbaubare und biokompatible polymere enthaltende zusammensetzung zur gewebebehandlung
EP1501558A1 (fr) Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine
US7074425B2 (en) Hemostatic compositions and methods
EP4069324B1 (fr) Pâte de thrombine fibrinogène fluide
EP3532026B1 (fr) Pansements hémostatiques s'appuyant sur la nanotechnologie
US20100266693A1 (en) Controlled release local anesthetic comprising a biologically active non-sulfated glycosaminoglycan matrix
EP4537859A1 (fr) Gel de fibrine et son procédé d'obtention
CA3097819C (fr) Méthode de reconstitution d’une thrombine sèche au moyen d’une première et d’une deuxième seringue, et utilisation pour la préparation d’une composition hémostatique
US20260083874A1 (en) Haemostatic composition
WO2025202384A1 (fr) Composition hémostatique
WO2025202390A1 (fr) Composition hémostatique
WO2025202367A1 (fr) Composition hémostatique
HK40100512A (en) Method for preparing a haemostatic composition
US20160038627A1 (en) Method of causing delayed hemostasis
HK40047052A (en) Method for preparing a haemostatic composition
HK40047052B (en) Method for preparing a haemostatic composition
Aktop et al. Effects of ankaferd blood stopper on soft tissue healing in warfarmn treated rats

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOECKER, HARTWIG,UNIVERSITAETSKLINIKUM AACHEN

Inventor name: KLEE, DORIS,LEHRST.FUER TEXTIL-UND MAKROMOL.CHEMIE

Inventor name: PEREIRA-PAZ, RUI-MIGUEL

Inventor name: GERHARDS, FRANK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOECKER, HARTWIG,DEUTSCHES WOLLFORSCHUNGSINST.DWI

Inventor name: KLEE, DORIS,LEHRST.FUER TEXTIL-UND MAKROMOL.CHEMIE

Inventor name: PEREIRA-PAZ, RUI-MIGUEL

Inventor name: GERHARDS, FRANK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051220